Aureka Biotechnologies is a pioneer in the next generation of antibody discovery and engineering via our three fundamental technologies. Our platforms integrate AI with high-throughput biology for a fast, closed-loop, integrative discovery process. AuraQuest accelerates antibody design via a unique synthetic biology design, while AuraGlow, an ultra-high-throughput screening system, evaluates functional performance. AuraPicasso, our generative AI engine, continuously refines antibody candidates using feedback from AuraQuest and AuraGlow. This closed-loop system enables fast iteration, ensuring the development of best-in-class therapeutics with enhanced efficacy and specificity. To date, we have delivered on challenges such as pH sensitive binders, dual-affinity molecules, and AI-first therapeutics.